Technology
ANALYTICAL INTELLIGENCE FOR PATIENT SUBGROUP DISCOVERY
Personalised medicine grounded in single-cell biology.
Genial introduces analytical intelligence for patient stratification, enabling quantitative and biologically interpretable comparison of unlabeled samples directly from single cell data, significantly improving the way scRNA-seq data can be used.
Omics-driven insight, supported by mathematical rigor.
Traditional scRNA-seq analytical tools reveal cell type composition and group-level differences.
Genial’s Patient Stratification PS INTELLIGENCE goes further by applying advanced graph-based methods.
Deep dive into patients’ profiles.
This enables:
- Mapping of biological similarity between patients
- Discovery of previously unrecognised patient subgroups
- Finer-grained, omics-driven patient stratification
Platform
GLANCE
A platform for the analysis and interpretation of complex omics data
From data to insight — with precision and clarity
GLANCE is a digital platform designed to support the secure, reproducible, and scalable analysis of complex omics data. It enables research and translational teams to move from raw data to biologically meaningful insight while maintaining scientific rigor and traceability.
The platform is intended for:
A platform for the analysis and interpretation of complex omics data
From data to insight — with precision and clarity
GLANCE is a digital platform designed to support the secure, reproducible, and scalable analysis of complex omics data. It enables research and translational teams to move from raw data to biologically meaningful insight while maintaining scientific rigor and traceability.
The platform is intended for:
- Pharma & Biotech companies
- Contract Research Organisations (CROs)
- Academic and translational researchers
The GLANCE Platform
GLANCE is a cloud-based, GPU-accelerated platform built to support the full analytical lifecycle of omics data—from raw data ingestion and quality control to advanced analysis and audit-ready reporting.
The platform is designed so domain experts can perform complex analyses without writing code, while bioinformatics teams retain full control over analytical parameters, versioning, and data provenance. This dual approach enables efficient collaboration without compromising scientific or technical oversight.
